160 related articles for article (PubMed ID: 36946317)
1.
Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Abaji R; Gagné V; Xu CJ; Spinella JF; Ceppi F; Laverdière C; Leclerc JM; Sallan SE; Neuberg D; Kutok JL; Silverman LB; Sinnett D; Krajinovic M
Oncotarget; 2017 Jul; 8(27):43752-43767. PubMed ID: 28574850
[TBL] [Abstract][Full Text] [Related]
3. Trypsin-encoding
Wolthers BO; Frandsen TL; Patel CJ; Abaji R; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grosjean M; Krajinovic M; Larsen E; Liang DC; Möricke A; Rasmussen KK; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Yang W; Zapotocka E; Gupta R; Schmiegelow K;
Haematologica; 2019 Mar; 104(3):556-563. PubMed ID: 30467200
[TBL] [Abstract][Full Text] [Related]
4. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Duarte X; Esteves S; Neto AM; Pereira F
Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
[TBL] [Abstract][Full Text] [Related]
6. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
[TBL] [Abstract][Full Text] [Related]
7. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement.
Alberts SR; Bretscher M; Wiltsie JC; O'Neill BP; Mokri B; Witzig TE
Leuk Lymphoma; 1999 Feb; 32(5-6):489-96. PubMed ID: 10048421
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
11. Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.
Athale UH; Flamand Y; Blonquist T; Stevenson KE; Spira M; Asselin BL; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2022 Aug; 69(8):e29581. PubMed ID: 35316569
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Elhasid R; Lanir N; Sharon R; Weyl Ben Arush M; Levin C; Postovsky S; Ben Barak A; Brenner B
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):367-70. PubMed ID: 11505079
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Ben Tanfous M; Sharif-Askari B; Ceppi F; Laaribi H; Gagné V; Rousseau J; Labuda M; Silverman LB; Sallan SE; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Clin Cancer Res; 2015 Jan; 21(2):329-34. PubMed ID: 24907114
[TBL] [Abstract][Full Text] [Related]
14. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
16. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.
Truelove E; Fielding AK; Hunt BJ
Leukemia; 2013 Mar; 27(3):553-9. PubMed ID: 23099335
[TBL] [Abstract][Full Text] [Related]
17. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Kondyli M; Tremblay DÉ; Rezgui A; Serfaty SA; Gagné V; Ribère M; Laverdière C; Leclerc JM; Tran TH; Sinnett D; Krajinovic M
Leuk Res; 2021 Oct; 109():106650. PubMed ID: 34198115
[No Abstract] [Full Text] [Related]
18. The risk factors for thrombosis in children with acute lymphoblastic leukemia.
Sivaslioglu S; Gursel T; Kocak U; Kaya Z
Clin Appl Thromb Hemost; 2014 Sep; 20(6):651-3. PubMed ID: 23364161
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Nowak-Göttl U; Heinecke A; von Kries R; Nürnberger W; Münchow N; Junker R
Thromb Res; 2001 Aug; 103(3):165-72. PubMed ID: 11672578
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
